Heparin-induced thrombocytopenia and arterial thrombosis: alternative therapies.
There are three distinct syndromes of heparin-induced thrombocytopenia: an acute reversible from seen immediately after intravenous bolus injection, a delayed-onset antibody-mediated form seen several days after the initiation of therapy, and an intermediate type characterized by mild thrombocytopenia developing just a few days after starting therapy. Delayed-onset heparin-induced thrombocytopenia, clinically the most important form, results from the formation of heparin-dependent antibodies that are directed against the platelet membrane. In the presence of heparin, these antibodies may induce in vitro or in vivo platelet aggregation. Consequently, the course may be complicated by arterial thromboses. Treatment of this syndrome includes the prompt cessation of heparin. Since continued or future anticoagulation is usually necessary, alternative means of anticoagulation have been explored. Oral anticoagulation is often started but requires several days to take effect. Other options include low-molecular-weight heparins, antiplatelet agents, prostacyclin analogues, and low-molecular-weight dextran. In vitro laboratory tests may be helpful in guiding alternative therapy in some, but not all cases. Unfortunately, none of these agents have proved to be uniformly effective and additional agents and clinical investigation are needed before a definitive option becomes available.
Department of Medicine, University of Massachusetts Medical School, Worcester 01655.
C
C
Cola
J
J
Ansell
D001241:Aspirin / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D011464:Epoprostenol / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects*; D006496:Heparinoids / Q000627:therapeutic use; D006497:Heparan Sulfate; D006801:Humans; D016285:Iloprost; D009336:Necrosis; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced / Q000473:pathology; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy; D013927:Thrombosis / Q000139:chemically induced* / Q000188:drug therapy
D001241:Aspirin; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D011464:Epoprostenol; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; D016285:Iloprost; D010975:Platelet Aggregation Inhibitors; C035838:danaparoid